論文・技術情報追加のお知らせ

1. Exploring potential associations between GLP-1RAs and depressive disorders: a pharmacovigilance study based on FAERS and VigiBase data.

セマグルタイドの抑うつ障害

対象DB：FAERS,VigiBase

2. Sex differences in drug-induced osteoporosis: a pharmacovigilance study based on the FAERS database.

薬剤性骨粗鬆症の性差リスク

対象DB：CVAR,FAERS

3. Pharmacovigilance of obeticholic acid: An analysis of the Food and Drug Administration Adverse Event Reporting System database.

オベチコール酸の有害事象解析

対象DB：FAERS

4. Evaluation and study of adverse reactions to imiglucerase based on the FAERS database.

イミグルセラーゼの安全性評価

対象DB：FAERS

5. Safety of infliximab and adalimumab in pediatric inflammatory bowel diseases: a disproportionality analysis from the FAERS database.

小児IBD治療薬IFXとADAの安全性

対象DB：FAERS

6. A pharmacovigilance study of vortioxetine based on data from the FDA adverse event reporting system.

ボルチオキセチンの安全性評価

対象DB：FAERS

7. Safety assessment of Osilodrostat: The adverse event analysis based on FAERS database by means of disproportionality analysis.

オシロドロスタットの有害事象解析

対象DB：FAERS

8. Real-world pharmacovigilance assessment of hepatotoxicity risk with HER2-Targeted drugs using FAERS database analysis.

HER2標的治療薬の肝毒性リスク

対象DB：FAERS

9. Torsade de Pointes and QT Prolongation Among Antifungal Triazoles: A Real-World, Retrospective, Observational, Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database.

抗真菌トリアゾールとTdP/QT延長

対象DB：FAERS

10. A real-world pharmacovigilance study of Certolizumab pegol based on FAERS database.

セルトリズマブ ペゴルの安全性評価

対象DB：FAERS

11. Beyond the Prostate: A Visionary Study on Ocular Impacts of Benign Prostatic Hyperplasia Drugs.

BPH薬と眼有害事象の関連

対象DB：FAERS

12. Infective pneumonia following the use of tumor necrosis factor-alpha inhibitors in inflammatory bowel disease patients: A real-world disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database.

TNFα阻害剤と感染性肺炎の関連

対象DB：FAERS

13. Cardiac Adverse Events Associated With Elotuzumab: A Disproportionality Analysis Using FDA Adverse Event Reporting System.

エロツズマブ関連心臓有害事象：FAERS不均衡性解析

対象DB：FAERS

14. Anaphylaxis to Penicillin: Harvesting Insights from the Food and Drug Administration's Adverse Event Reporting System.

ペニシリン誘発アナフィラキシーの疫学

対象DB：FAERS

15. Safety monitoring of Pfizer's Respiratory Syncytial Virus Vaccine in pregnant women in the Vaccine Adverse Event Reporting System (VAERS), 2023-2024, United States.

RSV母子ワクチン接種後の安全性評価

対象DB：FAERS,VAERS

16. Association between antibody-dependent cellular cytotoxicity activity of antitumor antibodies and infusion reactions: a pharmacovigilance analysis using the Japanese adverse drug event report database.

ADCC活性と抗腫瘍抗体の輸注反応リスクを解析

対象DB：JADER

17. Model-informed drug repurposing of proton pump inhibitors for the prevention of oxaliplatin induced peripheral neuropathy: A real-world data analysis and pharmacometrics approach.

オメプラゾールのOIPN抑制効果を実証データで評価

対象DB：JADER

18. Disproportionality Analysis of Intravitreal Ranibizumab, Aflibercept, and Brolucizumab for Cardiovascular and Cerebrovascular Events.

抗VEGF薬の心血管・脳血管リスクをJADERで分析

対象DB：JADER

19. Pharmacovigilance: Overview of Italian and European regulations, tools, and perspectives.

イタリアのPVシステム、進展と課題を評価

対象DB：EudraVigilance

20. Management of inpatient chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell malignancies: an analysis using the Japanese Diagnosis Procedure Combination database.

CAR-T療法後の周術期管理実態をRWEで解明

対象DB：DPC

21. Evaluating the Potential of Prevalent New User Design as an Alternative When New User Design is Impractical.

既存薬歴考慮の新規ユーザー設計がリスク評価に有効

対象DB：JMDC

22. Developing Data Analysis Skills for Local Medical Administration Personnel Using the National Database and Business Intelligence System (Tableau).

岡山県がNDB活用研修を成功裡に実施、資源公開

対象DB：NDB

23. Contemporary use of SGLT2 inhibitors in heart failure patients with diabetes mellitus: a comparison of DPP4 inhibitors in a nationwide electric health database of the superaged society.

SGLT2阻害剤は高齢HF患者の予後改善に有効

対象DB：NDB

24. Trend in prescription and treatment retention of molecular-targeted drugs in 121,131 Japanese patients with rheumatoid arthritis: A population-based real-world study.

RA治療薬の維持率は非TNF阻害薬が高い

対象DB：NDB

25. Regulatory-required post-marketing database studies in Japan could be leveraged to assess important potential risks as well as identified risks.

日本のPMDSは安全性重視のコホート研究が主流?

対象DB：MDV

26. First trimester antidepressant use and miscarriage: a comprehensive analysis in the Clinical Practice Research Datalink GOLD.

妊娠初期の抗うつ薬使用は流産リスク僅かに増加

対象DB：CPRD

27. Examining variations in the prevalence of hazardous opioid prescribing across general practices in England: a cross-sectional study.

危険なオピオイド処方は貧困層で多く、地域差が存在

対象DB：CPRD

28. The incidence and mortality of connective tissue diseases: a population-level cohort study in England from 2012 to 2023.

CTDの発生率は変動し、IIMとSScで死亡率が高い

対象DB：CPRD

29. Social determinants of heat-related mortality in England: a time-stratified case-crossover study using primary care records.

高齢者や女性、少数民族、貧困層が暑さで死亡リスク増

対象DB：CPRD